DOW JONES NEWSWIRES

Genta Inc. (GNTA) said the Food and Drug Administration has recommended a clinical trial for its cancer drug Genasense.

The FDA's Center for Drug Evaluation and Research ruled that available data are not adequate to support approval of the treatment for patients with chronic lymphocytic leukemia.

The biopharmaceutical company's chief medical officer, Dr. Loretta M. Itri, said the company would discuss the matter with clinical and regulatory authorities before deciding its next steps.

-By Kathy Shwiff, Dow Jones Newswires; 201-938-5975; Kathy.Shwiff@dowjones.com